MENU
 JPMA
  • Directions
  • Japanese
  • About JPMA

    About JPMA: Top

    • Message from the President
    • Overview of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • About Medicines

    About Medicines: Top

    • Medication Guide for the General Public
    • Clinical Trial Information
    • Working Together with Patients
  • Committee Updates

    Committee News Top

    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R & D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • Newsletter
  • Newsroom

    Newsroom Top

    • News Releases and Announcements
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA Video Content and Advertisements
  • The Office of Pharmaceutical Industry Research
Close
 JPMA

Return to Top

  • Patients and the General Public (About Medicines)
    Patients and the General Public (About Medications) Top
    • Medication Guide for the General Public
    • Clinical Trial Information
    • Working Together with Patients
  • Committee Updates
    Committee News Top
    • Code Compliance Committee
    • Pharmaceutical Industrial Policy Committee
    • Distribution Improvement Committee
    • Drug Evaluation Committee
    • Quality & Technology Committee
    • Biopharmaceutical Committee
    • Regulatory Affairs Committee
    • Intellectual Property Committee
    • R & D Committee
    • International Affairs Committee
    • Public Affairs Committee
    • Patient Cooperation Committee
    • ICH Project
    • APAC Project
    • Consumer Consultation Review Committee
    • Environmental Issue Committee
  • About JPMA
    About JPMA: Top
    • Message from the President
    • Overview of JPMA
    • Policies and Activities
    • Voluntary Standards
    • Vision, Policy Proposals
    • Organization
    • Member Companies
  • Policies and Activities
    Policies & Activities Top
    • Business Policy, Business Plan, and Implementation Plan
    • Committee Activities
    • Convention on Biological Diversity
  • Voluntary Standards
    Voluntary Standards Top
    • Code of Conduct
    • JPMA Code of Practice
    • Transparency Guideline for the Relation between Corporate Activities and Medical Institutions
    • Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations
    • Guidelines for the Preparation of Summaries of Product Characteristics for Prescription Drugs (Abbreviation: Preparation Guidelines)
    • Clinical Research
    • Basic Principles and Guidelines for Action on Biodiversity
    • Guidelines on Fair Competition at Meetings of the Japan Pharmaceutical Manufacturers Association
    • Agreements, Manuals, and Guidelines
  • Newsroom
    Newsroom Top
    • News Releases and Announcements
    • JPMA Newsletter
    • Updates
    • Publications
    • Events
    • JPMA Video Content and Advertisements
  • The Office of Pharmaceutical Industry Research  Opens in a new window
  • Social Media Policy
  • Website Terms of Use
  • Access
  • Japanese
  • Home
  • Committee Updates
  • Code Compliance Committee
  • Announcement from Code Compliance Committee

2026

  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • October 15, 2026

    Announcement Regarding the “Code of Practice Understanding Promotion Month” for the JPMA

  • October 14, 2026

    "FY 2026 Meeting of Code Management Officers and Practitioners" Held

  • September 14, 2026

    We have posted the “JPMA Code Awareness Month” video.

  • August 20, 2026

    We have posted the "Publicly Disclosed Information for FY 2025 Payments" from the Transparency Guideline for the Relation between Corporate Activities and Medical Institutions.

  • April 23, 2026

    Meeting of Compliance Managers and Practitioners for FY2025

  • April 15, 2026

    Workshop for Persons Responsible for Product Information Overview Management and Practical Responsibility for Product Information Overview Management in 2025" was held.

  • April 1, 2026

    Revision of the Transparency Guideline for the Relation between Corporate Activities and Medical Institutions

  • February 20, 2026

    Pamphlet (prepared in March 2026) and Explanation Japanese (revised on April 1, 2026) are now available for Transparency Guideline for the Relation between Corporate Activities and Medical Institutions.

  • 2026
  • 2025
  • 2024
  • 2023
  • 2022

Share this page

  • Post
  • Share

TOP

Site Search

  • Home
  • Committee Updates
  • Code Compliance Committee
  • Announcement from Code Compliance Committee
  • JPMA PR and Communications Activities
  • Pharmaceutical Research Institute
  • List of Non-Financial Information Disclosures by Member Companies
  • STOP AMR
  • About the JPMA
  • Policies and Activities
  • Voluntary Standards
  • Global Health
  • Newsroom
  • Patients and the General Public (About Medicines)
  • Clinical Trial Information
  • Committee Updates
  • JapanesePage will open in a new window.
  •  x
  •  Facebook
  •  YouTube
  • Site Map
  • Website Terms of Use
  • Basic Policy on Information Security
  • Social Media Policy
  • Links
  • Accessibility Policy
  • PRAISE-NET Login

© Japan Pharmaceutical Manufacturers’
’ Association (JPMA). All rights reserved.

Notification

This website uses automatic translation.
The translated content may not always be fully consistent with the original Japanese content.